| (Z)-Orantinib |
|
|
|
99.44% |
| (Z)-SU14813 |
|
|
|
|
| 1-Phenylindole |
|
|
|
99.78% |
| 10Z-Hymenialdisine |
|
|
|
|
| 2-Methyl-3-phenylquinoxaline |
|
|
|
98.70% |
| PDGFR-IN-2 |
|
|
|
99.37% |
| AC710 |
|
|
|
98.56% |
| AC710 Mesylate |
|
|
|
|
| AG 1295 |
|
|
|
99.86% |
| AG 370 |
|
|
|
97.0% |
| AGL 2043 |
|
|
|
|
| AK177 |
|
|
|
|
| Amuvatinib |
|
|
|
99.40% |
| Amuvatinib hydrochloride |
|
|
|
|
| Ansornitinib |
|
|
|
98.23% |
| Anti-Mouse PDGFRα Antibody (APA5) |
|
|
|
|
| Antifibrotic agent 1 |
|
|
|
|
| Avapritinib |
|
|
|
99.75% |
| Avapritinib-d3 |
|
|
|
|
| AX102 sodium |
|
|
|
98.15% |
| AXL-IN-13 |
|
|
|
98.03% |
| AXL/Angiokinase-IN-1 |
|
|
|
|
| AZD2932 |
|
|
|
98.16% |
| BI-4659 |
|
|
|
99.78% |
| Biotin-PDGFRβ Recombinant Human Active Protein Kinase |
|
|
|
|
| BLU-654 |
|
|
|
|
| BMS-605541 |
|
|
|
99.57% |
| BOT1711 |
|
|
|
|
| BRD4-IN-41 |
|
|
|
|
| CDK2/FLT4/PDGFRA-IN-1 |
|
|
|
|
| CGP 53716 |
|
|
|
99.15% |
| CHIR-124 |
|
|
|
99.05% |
| CHMFL-ABL/KIT-155 |
|
|
|
|
| cis-SU4312 |
|
|
|
|
| CP-673451 |
|
|
|
99.65% |
| Crenolanib |
|
|
|
99.30% |
| Crenolanib benzenesulfonate |
|
|
|
99.45% |
| CT52923 |
|
|
|
98.58% |
| DMPQ dihydrochloride |
|
|
|
99.10% |
| E4177 |
|
|
|
98.82% |
| E8431 |
|
|
|
97.34% |
| ENMD-2076 |
|
|
|
99.99% |
| ENMD-2076 Tartrate |
|
|
|
99.66% |
| Famitinib malate |
|
|
|
|
| FGFR1/VEGFR2-IN-2 |
|
|
|
|
| Gint4.T aptamer sodium |
|
|
|
94.50% |
| GSK190937 |
|
|
|
|
| GW296115 |
|
|
|
|
| GW694590A |
|
|
|
|
| GZD856 |
|
|
|
|
| GZD856 formic |
|
|
|
95.36% |
| Henatinib |
|
|
|
|
| Henatinib maleate |
|
|
|
|
| HG-7-85-01 |
|
|
|
98.14% |
| HSN748 |
|
|
|
|
| IHMT-TRK-284 |
|
|
|
|
| Ilorasertib |
|
|
|
99.86% |
| Ilorasertib hydrochloride |
|
|
|
98.48% |
| JI-101 |
|
|
|
98.99% |
| JI-101 hydrochloride |
|
|
|
|
| JNJ-10198409 |
|
|
|
99.58% |
| KBP-7018 |
|
|
|
|
| KBP-7018 hydrochloride |
|
|
|
|
| KG5 |
|
|
|
99.79% |
| Ki11502 |
|
|
|
99.30% |
| Ki20227 |
|
|
|
99.51% |
| KIT/PDGFRA-IN-1 |
|
|
|
|
| KN1022 |
|
|
|
|
| L 741742 |
|
|
|
99.28% |
| L 741742 hydrochloride |
|
|
|
|
| L-783277 |
|
|
|
|
| Labuxtinib |
|
|
|
98.74% |
| LY2457546 |
|
|
|
|
| MELK-8a |
|
|
|
98.32% |
| MET/PDGFRA-IN-1 |
|
|
|
|
| MET/PDGFRA-IN-2 |
|
|
|
|
| MT-125 |
|
|
|
98.73% |
| MT-125 free base |
|
|
|
98.67% |
| Multi-kinase inhibitor 1 |
|
|
|
99.05% |
| Multi-kinase inhibitor 3 |
|
|
|
|
| Multi-kinase inhibitor 4 |
|
|
|
|
| Multi-kinase-IN-1 |
|
|
|
|
| Multi-kinase-IN-2 |
|
|
|
|
| Multi-kinase-IN-3 |
|
|
|
|
| Multi-kinase-IN-5 |
|
|
|
|
| Myricanol |
|
|
|
98.93% |
| N-(p-Coumaroyl) Serotonin |
|
|
|
99.03% |
| N-(p-Coumaroyl) Serotonin (Standard) |
|
|
|
|
| N-Feruloylserotonin |
|
|
|
99.93% |
| Narazaciclib |
|
|
|
98.66% |
| NVP-ACC789 |
|
|
|
99.52% |
| Orantinib |
|
|
|
98.52% |
| Pazopanib-d3 hydrochloride |
|
|
|
|
| PD 174265 |
|
|
|
98.35% |
| PD-089828 |
|
|
|
98.07% |
| PD-161570 |
|
|
|
99.82% |
| PDGFR Tyrosine kinase-IN-1 |
|
|
|
99.07% |
| PDGFR Y1021 peptide (non-phosphorylation) |
|
|
|
|
| PDGFR Y1021 peptide (phosphorylation) |
|
|
|
|
| PDGFR-IN-1 |
|
|
|
98.84% |
| PDGFRA Human Pre-designed siRNA Set A |
|
|
|
|
| Pdgfra Mouse Pre-designed siRNA Set A |
|
|
|
|
| PDGFRA-IN-1 |
|
|
|
|
| PDGFRA/CAIX/XII-IN-1 |
|
|
|
98.10% |
| PDGFRalpha D842V Recombinant Human Active Protein Kinase |
|
|
|
|
| PDGFRalpha T674I Recombinant Human Active Protein Kinase |
|
|
|
|
| PDGFRalpha V561D Recombinant Human Active Protein Kinase |
|
|
|
|
| PDGFRB Human Pre-designed siRNA Set A |
|
|
|
|
| Pdgfrb Mouse Pre-designed siRNA Set A |
|
|
|
|
| PDGFRα kinase inhibitor 1 |
|
|
|
98.51% |
| PDGFRα kinase inhibitor 2 |
|
|
|
98.95% |
| PDGFRα kinase inhibitor 3 |
|
|
|
|
| PDGFRα kinase-IN-2 |
|
|
|
|
| PDGFRα/FLT3-ITD-IN-1 |
|
|
|
|
| PDGFRα/FLT3-ITD-IN-2 |
|
|
|
|
| PDGFRα/FLT3-ITD-IN-3 |
|
|
|
|
| PDGFRα/β/VEGFR-2-IN-1 |
|
|
|
|
| PEG40K unconjugated/naked AX102 sodium |
|
|
|
|
| Pegpleranib |
|
|
|
|
| Pegpleranib sodium |
|
|
|
98.38% |
| Pimicotinib |
|
|
|
99.92% |
| Pimicotinib hydrochloride |
|
|
|
|
| Pomalidomide-C5-Dovitinib |
|
|
|
|
| PP121 |
|
|
|
99.51% |
| PP487 |
|
|
|
|
| PP58 |
|
|
|
98.70% |
| Proinsulin C-peptide (human) |
|
|
|
99.54% |
| Quizartinib dihydrochloride |
|
|
|
99.81% |
| Regorafenib mesylate |
|
|
|
|
| RPR-101511 |
|
|
|
|
| S116836 |
|
|
|
99.78% |
| SA-PA |
|
|
|
|
| Sch 13835 |
|
|
|
|
| Seralutinib |
|
|
|
99.94% |
| SNX-7081 |
|
|
|
|
| SU 5402 |
|
|
|
|
| SU 5402 |
|
|
|
99.78% |
| SU-4313 |
|
|
|
99.31% |
| SU10944 |
|
|
|
|
| SU11652 |
|
|
|
99.18% |
| SU14813 |
|
|
|
99.11% |
| SU14813 maleate |
|
|
|
99.04% |
| SU16f |
|
|
|
99.36% |
| SU4312 |
|
|
|
99.74% |
| SU4984 |
|
|
|
99.70% |
| Sunitinib glucuronate |
|
|
|
95.0% |
| Sunitinib Malate |
|
|
|
99.74% |
| Sunitinib-platinum(IV) prodrug-1 |
|
|
|
|
| Sutetinib |
|
|
|
99.27% |
| Sutetinib maleate |
|
|
|
|
| TAK-593 |
|
|
|
99.66% |
| Tandutinib hydrochloride |
|
|
|
99.29% |
| Tandutinib sulfate |
|
|
|
|
| TG 100572 |
|
|
|
|
| TG 100572 Hydrochloride |
|
|
|
98.76% |
| TG 100801 |
|
|
|
98.61% |
| TG 100801 Hydrochloride |
|
|
|
|
| Tyrosine kinase-IN-11 |
|
|
|
98.75% |
| Tyrphostin A9 |
|
|
|
99.91% |
| Tyrphostin AG1296 |
|
|
|
99.69% |
| Tyrphostin AG1433 |
|
|
|
99.08% |
| Tyrphostin AG1433 hydrochloride |
|
|
|
|
| UNC9750 |
|
|
|
|
| Vasigrobart |
|
|
|
|
| VEGFR-2-IN-44 |
|
|
|
|
| VEGFR2-IN-84 |
|
|
|
|
| Velzatinib |
|
|
|
99.40% |
| Vorolanib |
|
|
|
99.78% |
| WQ-C-401 |
|
|
|
99.41% |
| Xanthinol |
|
|
|
|
| XL 999 |
|
|
|
99.01% |
| YH-0623 |
|
|
|
|
| Zeteletinib |
|
|
|
98.31% |
| Zeteletinib hemiadipate |
|
|
|
|
| β-Glucogallin |
|
|
|
99.82% |
| Lenvatinib-d4 |
|
|
|
99.59% |
| Lenvatinib-d5 |
|
|
|
|
| Lenvatinib-15N,d4 |
|
|
|
98.01% |
| Lenvatinib |
|
|
|
99.75% |
| Lenvatinib mesylate |
|
|
|
99.91% |
| Imatinib |
|
|
|
99.95% |
| Imatinib-d3 hydrochloride |
|
|
|
95.19% |
| Imatinib-d4 |
|
|
|
99.82% |
| Imatinib-d8 |
|
|
|
99.88% |
| Imatinib-13C,d3 |
|
|
|
|
| Rinucumab |
|
|
|
99.9% |
| Linifanib |
|
|
|
99.39% |
| Linifanib |
|
|
|
|
| Linifanib-d4 |
|
|
|
|
| Tandutinib |
|
|
|
99.48% |
| Dovitinib-d8 |
|
|
|
|
| Dovitinib |
|
|
|
99.88% |
| Dovitinib lactate |
|
|
|
99.75% |
| Dovitinib lactate hydrate |
|
|
|
|
| Quizartinib |
|
|
|
99.08% |
| Quizartinib-d8 |
|
|
|
|
| Olaratumab |
|
|
|
98.52% |
| Hypothemycin |
|
|
|
98.0% |
| Nintedanib |
|
|
|
99.90% |
| Nintedanib-d3 |
|
|
|
|
| Nintedanib-13C,d3 |
|
|
|
|
| Nintedanib-d8 |
|
|
|
99.90% |
| Nintedanib esylate |
|
|
|
99.96% |
| Pazopanib |
|
|
|
99.91% |
| Pazopanib-d6 |
|
|
|
98.0% |
| Pazopanib-13C,d3 |
|
|
|
|
| Pazopanib-d3 |
|
|
|
|
| Ponatinib-d8 |
|
|
|
99.16% |
| Ponatinib |
|
|
|
99.67% |
| Gomisin D |
|
|
|
99.56% |
| Tovetumab |
|
|
|
99% |
| Toceranib |
|
|
|
97.41% |
| Toceranib-d8 |
|
|
|
99.08% |
| Toceranib phosphate |
|
|
|
99.23% |
| Ponatinib hydrochloride |
|
|
|
99.76% |
| Trapidil |
|
|
|
98.0% |
| Telatinib |
|
|
|
99.37% |
| Flumatinib |
|
|
|
99.80% |
| Flumatinib-d3 |
|
|
|
99.9% |
| Famitinib |
|
|
|
98.13% |
| Xanthinol Nicotinate |
|
|
|
99.94% |
| Regorafenib-d3 |
|
|
|
98.0% |
| Regorafenib-13C,d3 |
|
|
|
|
| Regorafenib |
|
|
|
99.93% |
| Regorafenib Hydrochloride |
|
|
|
99.09% |
| Regorafenib monohydrate |
|
|
|
99.94% |
| Ripretinib |
|
|
|
98.71% |
| Imatinib Mesylate |
|
|
|
99.93% |
| Telatinib mesylate |
|
|
|
99.74% |
| Flumatinib mesylate |
|
|
|
99.80% |
| Masitinib mesylate |
|
|
|
99.98% |
| Sennoside B |
|
|
|
99.23% |
| Pazopanib-13C,d3 hydrochloride |
|
|
|
97.51% |
| Pazopanib Hydrochloride |
|
|
|
99.99% |
| Vesencumab |
|
|
|
99.34% |
| Sunitinib-d10 |
|
|
|
99.89% |
| Sunitinib-d4 |
|
|
|
|
| Sunitinib |
|
|
|
99.04% |
| Cediranib |
|
|
|
99.87% |
| Cediranib maleate |
|
|
|
99.95% |
| Chiauranib |
|
|
|
98.97% |
| Axitinib-13C,d3 |
|
|
|
97.80% |
| Axitinib |
|
|
|
99.84% |
| Masitinib |
|
|
|
99.66% |
| Methylnissolin |
|
|
|
99.92% |